Pharmaron Chooses Reaxys® To Enhance Productivity and Competitiveness

FRANKFURT, Germany, August 29, 2011 /PRNewswire/ --

- Reaxys is an Online Workflow Solution Used by Research Chemists to Fuel Their Drug Discovery Processes

Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today that Pharmaron, a premier drug R&D service provider for the pharmaceutical and biotech industry, has signed a multi-year contract with Elsevier, which will provide unlimited Reaxys access to all Pharmaron researchers. Reaxys will enable Pharmaron to continue to consolidate its scientific excellence and to stay competitive in drug R&D, and also ensure that Pharmaron has the best possible resources available to provide high-quality research and solutions to their customers.

"Our partners depend on the high-quality drug R&D services that we provide. The information our scientists have access to is a critical componentof our drug R&D services," said Dr. Tongqian Chen, Senior Vice President of Chemistry at Pharmaron. "Reaxys' proven track record in providing an unparalleled quality of information will allow our scientists in the labs to plan and execute in a more productive manner. We are delighted to have Elsevier as our scientific information providing partner and look forward to the productive collaboration."  

Pharmaron is a key player in the Chinese CRO industry, a preferred drug R&D service provider to global pharmaceutical and chemical companies. The increased emphasis on partnership and productivity has made validated information access indispensible. Consequently access to Reaxys' chemical information will be a significant aspect in helping Pharmaron continue to be a highly competitive and dynamic player in the industry.  

"Reaxys provides the relevant information that enables researchers to work effectively; we are committed to ensuring that researchers can immediately take their findings from Reaxys and apply them effectively in the lab," said Mark van Mierle, Managing Director, Pharma and Biotech Group, Elsevier. "We look forward to continuing to support Pharmaron's ongoing R&D work."

Reaxys® is a registered trademark owned and protected by Elsevier Properties SA and used under license.

About Pharmaron
Pharmaron is a premier R&D service provider for the pharmaceutical and biotech industries. Founded in 2003, Pharmaron invests in its people and facilities enabling the company to provide high quality R&D service across a number of disciplines, including chemistry, biology, DMPK, pharmacology and chemical development. Pharmaron is steadily growing to meet the needs of its customers. With more than 1,200 employees and operations in China and the U.S., Pharmaron delivers superior scientific services while maintaining close communication with customers. The company's current clients include small and large pharmaceutical companies in North America, Europe and Japan. Pharmaron's mission is to provide the highest quality R&D services while helping customers advance their projects in a timely and cost effective manner.

About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Tom Reller
Vice President, Global Corporate Relations Elsevier
+1-215-239-3508
[email protected]

SOURCE Elsevier

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED